作者: Ingmar Königsrainer , Stefan Beckert , Sven Becker , Derek Zieker , Tanja Fehm
DOI: 10.1007/S00423-011-0835-2
关键词:
摘要: Purpose Peritoneal recurrence of ovarian cancer is frequent after primary surgery and chemotherapy has poor long-term survival. De novo cytoreductive crucial with the potential to improve prognosis, especially when combined hyperthermic intraperitoneal (HIPEC).